Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
75% of Arab Israelis support Arab party joining government coalition post-war, survey reveals - 2Lucrative Positions in the Advancing Position Market of 2024
- 3He made a name for himself posting thirst traps on TikTok. Now he's the star of a wildly popular rom-com.
- 4Discovery of massive spider's web in Greece reveals unexpected behavior
- 5Ancient Egyptian pharaoh's boat is being reassembled in public at the Grand Egyptian Museum
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Remain Cool and Solid: Top Summer Food sources for 2024
- Doctors seek to understand why quitting antidepressants causes withdrawal for some
- NASA’s Pandora telescope will study stars in detail to learn about the exoplanets orbiting them
- Pick Your Number one sort of blossom
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- How one man's concern saved his brothers from heart disease
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Astounding Treehouses All over the Planet
